HOPHFHEMOGENYX PHARMACEUTICALS PLC.

About HEMOGENYX PHARMACEUTICALS PLC. (HOPHF)

HEMOGENYX PHARMACEUTICALS PLC. (HOPHF) is a Biotechnology company headquartered in London, ENG, United Kingdom whose shares trade over-the-counter on the Pink tier.

Hemogenyx Pharmaceuticals Plc, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood cancer. The company's lead product candidate is the HEMO-CAR-T therapy for the treatment and potential cure for relapsed and/or refractory acute myeloid leukemia. It also develops chimeric bait receptor to treat COVID-19 virus, as well as to treat brain cancers and/or certain neurodegenerative diseases; and CDX bi-specific antibody which eliminates hematopoietic stem cells/hematopoietic progenitors in a patient using bi-specific antibodies; and cell therapy products for bone marrow/hematopoietic stem cell transplantation.

HOPHF key facts

Ticker symbol

HOPHF

Market tier

Pink

Sector

Healthcare

Industry

Biotechnology

Headquarters

London, ENG, United Kingdom

Country of incorporation

GB

Shares outstanding

1,129,136,727

Reporting standard

International Reporting: LSE - London Stock Exchange

Audit status

Audited

Fiscal year end

12/31

Explore more: Biotechnology stocks · Healthcare sector · Pink stocks · OTC stocks starting with H